In vivo and in silico studies demonstrated that the anti-RA activity of pristimerin were mediated through the MAPK/Erk1/2, PI3K/Akt pathways and directing binding with TNF-α. This evidence concerns the gene MAPK3 and rheumatoid arthritis.